Medicover (Germany) Performance
| 5M0B Stock | EUR 17.64 0.30 1.67% |
On a scale of 0 to 100, Medicover holds a performance score of 12. The company secures a Beta (Market Risk) of -0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Medicover are expected to decrease at a much lower rate. During the bear market, Medicover is likely to outperform the market. Please check Medicover's semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to make a quick decision on whether Medicover's current price movements will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Medicover AB are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Medicover reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 46.7 M | |
| Total Cashflows From Investing Activities | -333.6 M |
Medicover |
Medicover Relative Risk vs. Return Landscape
If you would invest 1,502 in Medicover AB on November 8, 2024 and sell it today you would earn a total of 262.00 from holding Medicover AB or generate 17.44% return on investment over 90 days. Medicover AB is generating 0.2877% of daily returns assuming 1.7441% volatility of returns over the 90 days investment horizon. Simply put, 15% of all stocks have less volatile historical return distribution than Medicover, and 95% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medicover Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medicover's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medicover AB, and traders can use it to determine the average amount a Medicover's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.165
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 5M0B | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.74 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 12 88% of assets perform better |
Based on monthly moving average Medicover is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medicover by adding it to a well-diversified portfolio.
Medicover Fundamentals Growth
Medicover Stock prices reflect investors' perceptions of the future prospects and financial health of Medicover, and Medicover fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medicover Stock performance.
| Return On Equity | 0.0261 | |||
| Return On Asset | 0.024 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 2.94 B | |||
| Shares Outstanding | 71.58 M | |||
| Price To Earning | 46.07 X | |||
| Price To Book | 4.45 X | |||
| Price To Sales | 1.38 X | |||
| Revenue | 1.38 B | |||
| EBITDA | 274.9 M | |||
| Cash And Equivalents | 55.9 M | |||
| Cash Per Share | 0.42 X | |||
| Total Debt | 375.8 M | |||
| Debt To Equity | 116.80 % | |||
| Book Value Per Share | 3.19 X | |||
| Cash Flow From Operations | 216.7 M | |||
| Earnings Per Share | 0.24 X | |||
| Total Asset | 1.68 B | |||
About Medicover Performance
By analyzing Medicover's fundamental ratios, stakeholders can gain valuable insights into Medicover's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Medicover has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medicover has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Medicover AB provides diagnostic and healthcare services in Germany, Romania, Ukraine, Poland, Belarus, Moldova, Serbia, Turkey, Georgia, Bulgaria, India, and Hungary. Medicover AB was founded in 1995 and is headquartered in Stockholm, Sweden. MEDICOVER operates under Health Care Plans classification in Germany and is traded on Frankfurt Stock Exchange. It employs 20970 people.Things to note about Medicover AB performance evaluation
Checking the ongoing alerts about Medicover for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medicover AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medicover AB has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Medicover AB has accumulated 375.8 M in total debt with debt to equity ratio (D/E) of 116.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Medicover AB has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Medicover until it has trouble settling it off, either with new capital or with free cash flow. So, Medicover's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medicover AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medicover to invest in growth at high rates of return. When we think about Medicover's use of debt, we should always consider it together with cash and equity. | |
| About 13.0% of Medicover shares are owned by insiders or employees |
- Analyzing Medicover's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medicover's stock is overvalued or undervalued compared to its peers.
- Examining Medicover's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medicover's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medicover's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medicover's stock. These opinions can provide insight into Medicover's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Medicover Stock analysis
When running Medicover's price analysis, check to measure Medicover's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicover is operating at the current time. Most of Medicover's value examination focuses on studying past and present price action to predict the probability of Medicover's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicover's price. Additionally, you may evaluate how the addition of Medicover to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |